Mucosal Inductive-Site Antigen Sampling and B Cell Priming
trigger
Luminal viral particles or noninvasive enteric pathogens delivered by oral vaccination or natural exposure interact with the gut epithelial compartment and are sampled at mucosal immune inductive sites — Peyer's patches of the small intestine and lymphoid follicles of the colon — where naive B cells encounter antigen and initiate mucosal humoral priming. Environmental or tropical enteropathy, which disrupts intestinal mucosal barrier integrity and mucosal inductive-site function, diminishes seroconversion to oral rotavirus and oral poliovirus vaccines in low-income settings.
Downstream
-
CD4+ T Cell-Dependent Class Switching to IgA and Lamina Propria Plasma Cell Homing
Primed mucosal B cells receive CD4+ T cell help, switch to IgA, and home to the intestinal lamina propria and submucosa as antibody-secreting plasma cells and memory B cells.
Show evidence (2 references)
"Pathogenicity and immune response can be conceptualized in terms of the interaction of these enteric pathogens with the gut epithelial compartment, immune inductive sites (Peyer's patch of the small intestine and lymphoid follicles of the colon), and a common immune effector compartment in the..."
Establishes the anatomical and functional division between gut mucosal inductive sites (Peyer's patches and colonic lymphoid follicles) and the lamina propria effector compartment where protective antibody is secreted.
"Environmental enteropathy (a common disorder in children in some low-income countries that is associated with diminished gastrointestinal immunity) might also have a role in reduced vaccine effectiveness in developing countries123. Indeed, the presence of biomarkers of environmental enteropathy..."
Demonstrates that intact gastrointestinal mucosal immunity at the inductive site is required for efficient oral vaccine seroconversion, and that environmental enteropathy impairs this trigger step.
CD4+ T Cell-Dependent Class Switching to IgA and Lamina Propria Plasma Cell Homing
amplifier
Activated mucosal B cells depend on CD4+ T cell help to undergo class switch recombination to immunoglobulin A (IgA) and differentiate into IgA-secreting plasma cells and cross-reactive submucosal memory B cells that populate the intestinal lamina propria effector compartment. Serum and intestinal antigen-specific IgA levels serve as the primary immunological marker of mucosal vaccine take.
Downstream
-
Enteric Pathogen Luminal Attachment and Mucosal Epithelial Entry
Lamina propria plasma cells secrete polymeric IgA that is transcytosed into the gut lumen to target pathogen attachment and entry at the intestinal epithelium.
Show evidence (3 references)
"In adult mice, protection from rotavirus reinfection is almost absolute and is mostly mediated by intestinal IgA antibodies90, the production of which is largely dependent on the activation of CD4+ T cells89."
Establishes that protective intestinal IgA production depends on CD4+ T cell activation.
"Levels of total serum rotavirus-specific immunoglobulin A (IgA) antibodies, measured after infection, are currently the best marker of protection against rotavirus disease74, and the presence of anti-rotavirus IgA antibodies in serum is widely used as a marker of vaccine take, although the..."
Supports antigen-specific IgA production as the canonical human correlate of protection and marker of oral vaccine take.
"One study identified memory B cells in the submucosa of adult intestinal tissue that produced broadly cross-reactive and cross-neutralizing antibodies specific to VP5*; accordingly, recombinant VP5* might represent a broadly efficient candidate for a rotavirus vaccine191."
Confirms that human intestinal submucosal memory B cells produce broadly cross-neutralizing antibodies against enteric viral capsid proteins.
Enteric Pathogen Luminal Attachment and Mucosal Epithelial Entry
therapeutic vulnerability
Enteric viruses and noninvasive mucosal bacteria initiate infection at the intestinal epithelial surface by binding host cell-surface glycans or protein receptors — including rotavirus outer capsid VP4 (VP8*/VP5*) binding histo-blood group antigens and sialoglycans on mature villus enterocytes, Vibrio cholerae fimbrial adhesins and toxin-coregulated pilus mediating attachment and microcolony formation on small-intestinal epithelium, and poliovirus capsid binding CD155 (PVR) on alimentary mucosal cells. This pathogen attachment and entry step is the module's key conformance and therapeutic target: conforming disorder entries align their primary luminal attachment or epithelial entry node here, and oral mucosal vaccines direct their inhibitory target_mechanisms edge at that conforming node.
Used by disorders
Cholera
as Colonization and Biofilm Formation
Downstream
-
Luminal Secretory IgA Immune Exclusion and Epithelial Attachment Blockade
When intercepted by vaccine-induced luminal secretory IgA, pathogen surface adhesins and capsid proteins are sterically blocked from engaging host epithelial receptors.
Show evidence (2 references)
"V cholerae, the representative noninvasive pathogen, has fimbrial adhesins that mediate attachment and colonization of the luminal surface of epithelial cells where organisms secrete cholera toxin (CT), a potent enterotoxin that induces a voluminous diarrhea via adenylate cyclase-dependent..."
Establishes luminal attachment and colonization of gut epithelial cells via surface adhesins as the primary pathogen step targeted by mucosal secretory IgA.
"Rotavirus attachment to host cells is mediated by the outer capsid protein VP4 (through its VP8* domain37) and binding partners on the host cell surface, including sialoglycans (such as gangliosides GM1 and GD1a) and histo-blood group antigens (HBGAs)"
Identifies the viral capsid adhesin (VP4/VP8*) and host epithelial glycan receptors (sialoglycans and HBGAs) that mediate enterocyte attachment and serve as the target of neutralizing mucosal antibodies.
Luminal Secretory IgA Immune Exclusion and Epithelial Attachment Blockade
central effector
Secretory IgA (sIgA) delivered to the luminal surface of intestinal epithelial cells binds pathogen surface adhesins and capsid proteins — including rotavirus outer capsid spike protein VP4 (VP8*/VP5*) and VP7, Vibrio cholerae O-antigen lipopolysaccharide and fimbrial adhesins, and poliovirus capsid proteins — physically blocking attachment to host epithelial receptors (such as histo-blood group antigens, sialoglycans, or CD155) and preventing enterocyte entry.
Downstream
-
Restriction of Mucosal Replication and Fecal Shedding
Blocking epithelial attachment and enterocyte entry prevents productive luminal replication and reduces the titer and duration of fecal pathogen shedding.
Show evidence (2 references)
"V cholerae, the representative noninvasive pathogen, has fimbrial adhesins that mediate attachment and colonization of the luminal surface of epithelial cells where organisms secrete cholera toxin (CT), a potent enterotoxin that induces a voluminous diarrhea via adenylate cyclase-dependent..."
Directly establishes that secretory IgA directed against pathogen surface components prevents attachment to gut epithelial cells, the central immune-exclusion mechanism of this module.
"Although the immune system is redundant, almost all current vaccines work through antibodies in serum or on mucosa that block infection or bacteremia/viremia and thus provide a correlate of protection."
Confirms across vaccine classes that mucosal antibodies act by blocking initial infection at the mucosal surface.
Restriction of Mucosal Replication and Fecal Shedding
effector
By preventing luminal attachment and enterocyte infection, mucosal sIgA curtails viral or bacterial replication in the intestinal tract and reduces both the quantity (titer) and duration of fecal pathogen excretion upon subsequent exposure. Parenteral inactivated vaccines (such as IPV in naive infants) do not directly induce primary intestinal sIgA, but boost waned intestinal mucosal immunity in previously mucosally primed individuals and shorten viral shedding duration and titer.
Downstream
-
Interruption of Fecal-Oral Transmission and Protection Against Enteric Disease
Reduced mucosal replication and fecal shedding prevents severe diarrheal or invasive disease in the vaccinee and interrupts community fecal-oral transmission.
Show evidence (2 references)
"While IPV on its own in naïve infants does not induce intestinal mucosal immunity, an ever-increasing body of evidence supports that IPV-vaccinated infants excrete poliovirus for significantly shorter periods and with a lower quantity (lower viral titer) after challenge with vaccine virus or..."
Contrasts primary intestinal mucosal immunity with parenteral immunization and identifies reduction in the duration and titer of fecal viral excretion as the functional readout of mucosal effector immunity.
"The boosting by IPV on waned mucosal immunity in previously OPV immunized individuals after a bOPV (types 1 + 3) challenge dose was shown to be greater than an additional dose of bOPV."
Demonstrates that mucosal priming establishes a memory compartment whose intestinal shedding-reduction capacity can be boosted upon re-exposure or parenteral boosting.
Interruption of Fecal-Oral Transmission and Protection Against Enteric Disease
consequence
The organism- and population-level consequence of mucosal sIgA immune exclusion is protection of the immunized host against severe secretory/osmotic diarrhea (in rotavirus and cholera) or viremic CNS invasion (in poliomyelitis), coupled with interruption of fecal-oral transmission in the community.
Show evidence (2 references)
"OPV became the main vaccine of choice for the GPEI due to its ease of use, low cost and ability to induce mucosal immunity, required for preventing transmission"
Establishes that vaccine-induced intestinal mucosal immunity is the mechanism required to interrupt fecal-oral transmission at the population level.
"Both vaccines are highly effective in preventing severe rotavirus disease in high-income countries117 but reduce the incidence of severe rotavirus disease by ~50–60% in many low-income countries118–120."
Quantifies the clinical consequence of oral rotavirus vaccination in preventing severe enteric disease across high- and low-income settings.